Abstract
Knowledge of candidate gene polymorphisms in a population is useful for a variety of gene-disease association studies, particularly for some complex traits. A number of candidate genes, a majority of them from the monoaminergic pathway in the brain, have been very popular in association studies with schizophrenia, a neuropsychiatric disorder. In this study diallelic/multiallelic polymorphisms in some dopaminergic, serotonergic and membrane-phospholipid-related genes have been evaluated in a control population recruited from North India. Association, if any, of these allelic variants with schizopherenia has been tested using a case-control approach. The case data have been taken from our published family-based association studies in schizophrenia. Of the eight genes tested in this study, association with schizophrenia was observed for only two gene polymorphisms, one in the promoter region of the serotonin 2A receptor gene and the other in the tryptophan hydroxylase gene. One new allele for the dopamine transporter gene (with eight repeats, 570-bp size), not reported in any population so far, has been identified in one individual in our sample. The data generated in this study, besides providing a normative background for various disease association studies, are a significant contribution to the population-specific genome database, a currently growing requirement.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
Atack J. R. 1996 Inositol monophosphatase. The putative therapeutic target for lithium.Brain Res. Rev. 22, 183–190.
Bassett A. S. and Chow E. W. 1999 22q11 deletion syndrome: a genetic subtype of schizophrenia.Biol. Psychiatr. 46, 882–891.
Berridge M. J., Downes C. P. and Hanley M. R. 1982 Lithium amplifies agonist dependent phosphatidylinositol responses in brain and salivary glands.Biochem. J. 206, 587–595.
Berridge M. J., Downes C. P. and Hanley M. R. 1989 Neural and developmental actions of lithium: a unifying hypothesis.Cell 59, 411–419.
Carlsson A. 1988 The current status of the dopamine hypothesis of schizophrenia.Neuropsychopharmacology 1, 179–186.
Chowdari K. V., Brandstaetter B., Semwal P., Bhatia T., Deshpande S., Reddy R., Wood J., Weinberg C. R., Thelma B. K. and Nimgaonkar V. L. 2001 Association studies of cytosolic phospholipase A2 polymorphisms and schizophrenia among two independent family based samples.Psychiatr. Genet. 11, 207–212.
Crocq M. A., Mant R., Asherson P., Williams J., Hode Y., Mayerova A.et al. 1992 Association between schizophrenia and homozygosity at the dopamine D3 receptor gene.J. Med. Genet. 48, 74–77.
Daniels J. K., Williams N. M., Williams J., Jones L. A., Cardno A. G., Murphy K. C., Spurlock G., Riley B., Scambler P., Asherson P., McGuffin P. and Owen M. J. 1996 No evidence for allelic association between schizophrenia and a polymorphism determining high or low catechol O-methyltransferase activity.Am. J. Psychiatr. 153, 268–270.
Gattaz W. F., Kollisch M., Thuren T., Virtanen J. A. and Kinnunen P. K. 1987 Increased plasma phospholipase-A2 activity in schizophrenic patients: reduction after neuroleptic therapy.Biol. Psychiatr. 22, 421–426.
Gattaz W. F., Hubner C. V., Nevalainen T. J., Thuren T. and Kinnunen P. K. 1990 Increased serum phospholipase A2 activity in schizophrenia: a replication study.Biol. Psychiatr. 28, 495–501.
Gattaz W. F., Schmitt A. and Maras A. 1995 Increased platelet phospholipase A2 activity in schizophrenia.Schizophr. Res. 16, 1–6.
Gottesman I. I. and Shields J. 1982Schizophrenia: the epigenetic puzzle. Cambridge University Press, Cambridge.
Horrobin D. F., Glen A. I. and Vaddadi K. 1994 The membrane hypothesis of schizophrenia.Schizophr. Res. 13, 195–207.
Jaber M., Jones S., Giros B. and Caron M. G. 1997 The dopamine transporter: a crucial component regulating dopamine transmission.Movement Disorders 12, 629–633.
Jequier E., Robinson D. S., Lovenberg W. and Sjoerdsma A. 1969 Further studies on tryptophan hydroxylase in rat brain stem and beef pineal.Biochem. Pharmacol. 18, 1071–1081.
Kaufman S. 1987 The enzymology of the aromatic amino acid hydroxylases. InAmino acids in health and disease: new perspective. (ed. S. Kaufman), pp. 205–232. Alan R. Liss, New York.
Lappalainen J., Zhang L., Dean M., Oz M., Ozaki N., Yu D. H., Virkkunen M., Weight F., Linnoila M. and Goldman D. 1995 Identification, expression, and pharmacology of a Cys23-Ser23 substitution in the human 5-HT2c receptor gene (HTR2C).Genomics 27, 274–279.
Mann J. J., Malone K. M., Nielsen D. A., Goldman D., Erdos J. and Gelernter J. 1997 Possible association of a polymorphism of the tryptophan hydroxylase gene with suicidal behaviour in depressed patients.Am. J. Psychiatr. 154, 1451–1453.
Matthyse S. 1973 Antipsychotic drug actions: a clue to the neuropathology of schizophrenia?Fed. Proc. 32, 200–205.
Nielsen D. A., Dean M. and Goldman D. 1992 Genetic mapping of the human tryptophan hydroxylase gene on chromosome 11, using an intronic conformational polymorphism.Am. J. Hum. Genet. 51, 1366–1371.
Nielsen D. A., Goldman D., Virkkunen M., Tokola R., Rawlings R. and Linnoila M. 1994 Suicidality and 5-hydroxyindoleacetic acid concentration associated with a tryptophan hydroxylase polymorphism.Arch. Gen. Psychiatr. 51, 34–38.
Nielsen D. A., Jenkins G. L., Stefanisko K. M., Jefferson K. K. and Goldman D. 1997 Sequence, splice site and population frequency distribution analyses of the polymorphic human tryptophan hydroxylase intron 7.Mol. Brain Res. 45, 145–148.
Nielsen D. A., Virkkunen M., Lappalainen J., Eggert M., Brown G. L., Long J. C., Goldman D. and Linnoila M. 1998 A tryptophan hydroxylase gene marker for suicidality and alcoholism.Arch. Gen. Psychiatr. 55, 593–602.
Numberger J. I. Jr., Blehar M. C., Kaufmann C. A., York-Cooler C., Simpson S. G., Harkavy-Friedman J., Severe J. B., Malaspina D. and Reich T. 1994 Diagnostic interview for genetic studies. Rationale, unique features, and training. NIMH Genetics Initiative.Arch. Gen. Psychiatr. 51, 849–859; discussion 863–864.
Prasad S., Deshpande S., Bhatia T., Wood J., Nimgaonkar V. L. and Thelma B. K. 1999 An association study of schizophrenia among Indian families.Am. J. Med. Genet. 88, 298–300.
Prasad S., Semwal P., Deshpande S., Bhatia T., Nimgaonkar V. L. and Thelma B. K. 2002 Molecular genetics of schizophrenia: past, present and future.J. Biosci. 27 (suppl. 1) 101–118.
Rao D., Jonsson E.G., Pauss S., Ganguli R., Nothen M. and Nimgaonkar V. L. 1998 Schizophrenia and the serotonin transporter gene.Psychiatr. Genet. 8, 207–212.
Reddy M. V. and Chandrashekar C. R. 1998 Prevalence of mental and behavioural disorders in India, a metaanalysis.Indian J. Psychiatr. 40, 149–157.
Risch N. and Merikangas K. 1996 The future of genetic studies of complex human diseases.Science 273, 1516–1517.
Ross B. M., Hudson C., Erlich J., Warsh J. J. and Kish S. J. 1997 Increased phospholipid breakdown in schizophrenia. Evidence for the involvement of a calcium-independent phospholipase A2.Arch. Gen. Psychiatr. 54, 487–494.
Ross B. M., Turenne S., Moszczynska A., Warsh J. J. and Kish S. J. 1999 Differential alteration of phospholipase A2 activities in brain of patients with schizophrenia.Brain Res. 821, 407–413.
Roth B. L. and Meltzer H. Y. 1995 The role of serotonin in schizophrenia. InPsychopharmacology, the fourth generation of progress (ed. F. E. Bloom and D. J. Kuprerpp), pp. 1215–1227. Raven Press, New York.
Rotondo A., Schuebel K., Bergen A., Aragon R., Virkkunen M., Linnoila M., Goldman D. and Nielsen D. 1999 Identification of four variants in the tryptophan hydroxylase promoter and association to behavior.Mol. Psychiatr. 4, 360–368.
Segman R. H., Ebstein R. P., Heresco-Levy U., Gorfine M., Avnon M., Gur E., Nemanov L. and Lerer B. 1997 Schizophrenia, chronic hospitalisation and the 5-HT2c receptor gene.Psychiatr. Genet. 7, 75–78.
Semwal P., Prasad S., Bhatia T., Deshpande S., Wood J., Nimgaonkar V. L. and Thelma B. K. 2001 Monoaminergic genes and their polymorphism among North Indians with schizophrenia: a family based analysis.Mol. Psychiatr. 6, 220–224.
Sokoloff P., Giros B., Martres M. P., Bouthenet M. L. and Schwartz J. C. 1990 Molecular cloning and characterisation of a novel dopamine receptor (D3) as a target for neuroleptics.Nature 347, 146–151.
Spurlock G., Williams J., Daniels J., Owen M. and McGuffin P. 1995 The European multi-centre study of susceptibility gene associations in schizophrenia: typing the 5HT-2R gene.Psychiatr. Genet. 5, 64–65.
Steen V. M., Lovlie R., Osher Y., Belmaker R. H., Berle O. and Gulbrandsen A. K. 1998 The polymorphic inositol polyphosphate-1-phosphatase gene as a candidate for pharmacogenetic prediction of lithium-responsive manic-depressive illness.Pharmacogenetics 8, 259–268.
Tamminga C. A. 1998 Serotonin and schizophrenia [editorial].Biol. Psychiatr. 44, 1079–1080.
Vandenberg D. J., Perisco A. M., Hawkins A. L., Griffin C. A., Li X., Jabs E. W. and Uhi G. R. 1992 Human dopamine transporter gene (DAT1) maps to chromosome 5p15.3 and displays a VNTR.Genomics 14, 1104–1106.
Warren J., Peacock J. T., Rodriguez L. C. and Fink J. K. 1993 AnMspI polymorphism in the human serotonin receptor gene (HTR2): detection by DGGE and RFLP analysis.Hum. Mol. Genet. 2, 338–342.
Wei, J., Lee K.-H. and Hemmings G. P. 1998 Is the cPLA2 gene associated with schizophrenia?Mol. Psychiatr. 3, 480–482.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Semwal, P., Prasad, S., Varma, P.G. et al. Candidate gene polymorphisms among North Indians and their association with schizophrenia in a case-control study. J Genet 81, 65–71 (2002). https://doi.org/10.1007/BF02715902
Received:
Issue Date:
DOI: https://doi.org/10.1007/BF02715902